The third quarter is now underway, and with earnings season starting this week analysts will be closely monitoring reports from companies to see how business was in the second quarter. With a ton of companies reporting over the next three weeks, and the markets definitely expecting the worst from Greece, stocks investors need to tread carefully when looking for new ideas. Some analysts on Wall Street are aggressively touting energy stocks.
A new report from Jefferies highlights the firm’s top growth stocks to buy. Two are new initiations and could make good sense for aggressive investors with capital to put to work in search of fresh ideas.
Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s first approved drug, Kerydin (tavaborole) topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of onychomycosis of the toenails. In July 2014, Anacor entered into an exclusive agreement with Sandoz, a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes Kerydin in the United States.
Anacor’s lead product development candidate is AN2728, an investigational non-steroidal topical PDE-4 inhibitor for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. Beyond Kerydin and AN2728, Anacor has discovered three investigational compounds that it has out-licensed for further development.
The analysts feel that the potential value that could be awarded to AN2728 given updated pricing assumptions and various net sales forecasts is huge. Their analysis suggests that if the drug achieves $1 billion in peak sales, shares of Anacor could be worth $100 or more. With Phase 3 data due out next month, the potential for investors is huge if the data is positive.
The Jefferies price target for the stock is raised from $70 to $80. The Thomson/First Call consensus price target is $75. The stock closed trading most recently at $78.59.